GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Distribution » Vital KSK Holdings Inc (TSE:3151) » Definitions » Research & Development

Vital KSK Holdings (TSE:3151) Research & Development : 円0 Mil (TTM As of Sep. 2024)


View and export this data going back to 2009. Start your Free Trial

What is Vital KSK Holdings Research & Development?

Research & Development is the aggregate amount of research and development expenses during the year. Vital KSK Holdings's Research & Development for the three months ended in Sep. 2024 was 円0 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Sep. 2024 was 円0 Mil.

Vital KSK Holdings Research & Development Historical Data

The historical data trend for Vital KSK Holdings's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vital KSK Holdings Research & Development Chart

Vital KSK Holdings Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Vital KSK Holdings Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Vital KSK Holdings Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was 円0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vital KSK Holdings  (TSE:3151) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Vital KSK Holdings Research & Development Related Terms

Thank you for viewing the detailed overview of Vital KSK Holdings's Research & Development provided by GuruFocus.com. Please click on the following links to see related term pages.

Vital KSK Holdings Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Distribution » Vital KSK Holdings Inc (TSE:3151) » Definitions » Research & Development
Comparable Companies
TSE:3183 SSE:3055 NGO:7488 TSE:7634 TSE:2689 TSE:7681 TSE:9265 TSE:7476 TSE:8129 MCK COR CAH HSIC SHSE:601607 HKSE:01099 MIL:AMP NZSE:EBO XSWX:GALE TSE:7459 TSE:2784
Traded in Other Exchanges
N/A
Address
1-1-12 Tsurumaki, Setagaya-ku, JPN, 154-0016
Website
http://www.vitalksk.co.jp
Vital KSK Holdings Inc engaged in the wholesale and retail of pharmaceutical products. It operates through the Pharmaceutical Wholesale and Other segments. The Pharmaceutical Wholesale segment sells medicines, diagnostics, and medical devices to hospitals, medical institutions, and health practitioners. The Other segment includes retail of pharmaceutical products, wholesale of agrochemical and veterinary drugs, transportation, nursing care services, and medical consultancies. All the business activity of the group is primarily functioned through Japan and distributes its product within the Korean and to overseas market.

Vital KSK Holdings Headlines

No Headlines